1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ESC: Alnylam’s Aim For First-Line Amvuttra Use Looks Dicey

 
• By Elizabeth Cairns

The full pivotal data in ATTR cardiomyopathy suggest the transthyretin silencer could find a niche as an add-on to Pfizer’s established drug Vyndamax.    

Heart shaped pills on a black background
• Source: Alamy

Following their toplining in June, the keenly awaited full results of the pivotal HELIOS-B trial of Alnylam Pharmaceuticals Inc.’s Amvuttra in transthyretin amyloidosis with cardiomyopathy (ATTR-CM) have turned out to be something of a disappointment.

Key Takeaways
  • Full data from the HELIOS-B trial of Alnylam’s Amvuttra in transthyretin amyloidosis with cardiomyopathy look weaker than data on Pfizer’s Vyndamax and BridgeBio’s acoramidis.

The data, presented at the annual congress of the European Society of Cardiology in London on 30 August, suggest that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

More from R&D

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.